natgillin/translations-raw huggingface dataset:
a p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate combination therapy using the Mann-Whitney U test. b p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy using the Mann-Whitney U test
a Vrednost p se nanaša na parno primerjavo monoterapije z metotreksatom in kombinirane terapije z zdravilom Humira/metotreksatom z Mann-Whitneyevim testom U b Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in kombinirane terapije z zdravilom Humira/metotreksatom z Mann-Whitneyevim testom U c Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in monoterapije z metotreksatom z Mann-Whitneyevim testom U.
a p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate combination therapy using the Mann-Whitney U test. b p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy using the Mann-Whitney U test
a Vrednost p se nanaša na parno primerjavo monoterapije z metotreksatom in kombinirane terapije z zdravilom Humira/metotreksatom z Mann-Whitneyevim testom U b Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in kombinirane terapije z zdravilomHumira/metotreksatom z Mann-Whitneyevim testom U c Vrednost p se nanaša na parno primerjavo monoterapije z zdravilom Humira in monoterapije z metotreksatom z Mann-Whitneyevim testom U.
a p-values based on Chi-squared test.
a vrednosti p na podlagi testa hi-kvadrat
a P-values by logrank test.
a P-vrednosti po log-rank testu.
a p-values compared efalizumab with placebo using logistic regression including baseline PASI score, prior treatment for psoriasis and geographical region as covariates.
a p-vrednosti primerjave efalizumaba s placebom z uporabo logistične regresije vključno z izhodišnim PASI izvidom, predhodnim zdravljenjem psoriaze in geografsko regijo kot
a p<0.00001 comparison with vPDT control b Comparative control up to Month 3.
a p<0,00001 za primerjavo s kontrolno skupino z vPDT
a p<0.001 Humira vs. placebo b p<0.001 Humira vs. methotrexate c p<0.01 Humira vs. placebo d p<0.05 Humira vs. methotrexate
a p < 0,001 zdravilo Humira v primerjavi s placebom b p < 0,001 zdravilo Humira v primerjavi z metotreksatom c p < 0,01 zdravilo Humira v primerjavi s placebom d p < 0,05 zdravilo Humira v primerjavi z metotreksatom
a p<0.001 versus placebo
a p < 0,001 glede na placebo
a p<0.001 versus placebo
a p < 0,001 glede na placebo a p < 0,001 glede na placebo
A pack containing 180 x 1 of 3 mg PVC/Aluminium perforated unit dose blisters (6 pouches) and 2 spare Insulin Release Units (IRU)
pakiranje, ki vsebuje 180 x 1 3-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija (6 vrečk) in 2 rezervna nastavka za sproščanje insulina (Insulin release unit - IRU)
A pack containing 270 x 1 of 1 mg PVC/Aluminium perforated unit dose blisters (9 pouches) and 6 spare Insulin Release Units (IRU)
pakiranje, ki vsebuje 270 x 1 1-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija (9 vrečk) in 6 rezervnih nastavkov za sproščanje insulina (Insulin release unit - IRU)
A pack containing 270 x 1 of 3 mg PVC/Aluminium perforated unit dose blisters (9 pouches) and 6 spare Insulin Release Units (IRU)
pakiranje, ki vsebuje 270 x 1 3-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija (9 vrečk) in 6 rezervnih nastavkov za sproščanje insulina (Insulin release unit - IRU)
A pack containing 30, 60, 90, 180 and 270 x 1 of 1 mg PVC/Aluminium perforated unit dose blisters
pakiranje, ki vsebuje 30, 60, 90, 180 in 270 x 1 1-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija
A pack containing 30, 60, 90, 180 and 270 x 1 of 3 mg PVC/Aluminium perforated unit dose blisters
pakiranje, ki vsebuje 30, 60, 90, 180 in 270 x 1 3-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija
A pack containing 60 x 1 of 1 mg PVC/Aluminium perforated unit dose blisters (2 pouches) and 2 spare Insulin Release Units (IRU)
pakiranje, ki vsebuje 60 x 1 1-mg perforiran pretisni omot za enkratni odmerek iz PVC/aluminija (2 vrečki) in 2 rezervna nastavka za sproščanje insulina (Insulin release unit - IRU)
A pack of 30 or 90 soft capsules is provided.
Na voljo je pakiranje po 30 ali 90 mehkih kapsul.
a pack of two units with 2 x 1 vial containing 1g of powder (3.3 mg eptotermin alfa) and 2 x 1 vial containing 230 mg carmellose powder.
pakiranje z dvema enotama vsebuje 2 x 1 vialo z 1 g praška (3,3 mg eptotermina alfa) in 2 x 1 vialo z 230 mg karmeloznega praška
A painful rash of dark red spots under the skin which do not go away when you put pressure on them.
Boleč izpuščaj ali temno rdeče pike pod kožo, ki ob pritisku ne izginejo.
A painful tear or abnormal connection of the tissue in your anus
boleča strganina ali nenormalna vezava tkiva v anusu
A painkiller that prevents fever can be given before each injection and for 24 hours after injection to reduce the influenza (flu)-like symptoms that may occur during the first few months of treatment.
Da bi zmanjšali gripi podobne simptome, ki se lahko pojavijo v prvih mesecih zdravljenja, lahko bolnik pred injiciranjem in 24 ur po njem dobi zdravilo proti bolečinam, ki preprečuje povišano telesno temperaturo.
a Paired t-test
a Preizkus dvojic
A pale yellow to light brown lyophilised cake or powder.
liofilizirana pogača ali prašek bledo rumene do svetlo rjave barve
A pandemic can affect most countries and regions around the world.
Pandemija lahko prizadene večino držav in območij po svetu.
A pandemic can affect most countries and regions around the world.
Pandemija lahko prizadene večino držav in območij po vsem svetu.
A pandemic can affect most countries and regions around the world.
Pandemija lahko prizadene večino držav in regij po vsem svetu.
A pandemic can affect most countries and regions around the world.
Prizadene lahko večino držav in območij po vsem svetu.
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin alfa and perform anti- erythropoietin antibody testing.
Pri paradoksalnem znižanju ravni hemoglobina in razvoju hude anemije, povezane z nizkim številom retikulocitov, je treba prekiniti zdravljenje z epoetinom alfa in opraviti preiskave za protitelesa proti eritropoetinu.
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti- erythropoietin antibody testing.
Paradoksalno zmanšanje koncentracije hemoglobina in pojav hude anemije, povezane z majhnim številom retikulocitov pomeni, da je treba zdravljenje z epoetinom prekiniti takoj in narediti testiranje za protitelesa proti eritropoetinu.
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti- erythropoietin antibody testing.
Paradoksno znižanje vrednosti hemoglobina in razvoj hude anemije, povezane z nizkim številom retikulocitov, zahteva takojšnjo prekinitev zdravljenja z epoetinom in testiranje na protitelesa proti eritropoetinu.
A part of the daily insulin dose ("basal rate") is infused continuously by the implantable pump and the remaining part of the daily dose is administered by the patient, using the same pump, as a bolus before meals.
Del dnevnega odmerka insulina ("bazalna hitrost") stalno infundira implantabilna črpalka, preostanek dnevnega odmerka pa si da bolnik z uporabo iste črpalke v obliki bolusa pred obroki.
A part of the pre-filled pen, the needle cover, contains latex.
Del napolnjenega peresnika, to je ščitnik igle, vsebuje lateks.
A part of the pre-filled syringe, the needle cover, contains latex.
Del napolnjene injekcijske brizge, to je ščitnik igle, vsebuje lateks.
A partially used multidose vial must be discarded immediately if:
Delno uporabljeno večodmerno vialo takoj zavrzite, če:
A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.
Bolnik, ki jemlje rivastigmin peroralno v odmerku 12 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 9,5 mg/24 h.
A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Bolnik, ki jemlje rivastigmin peroralno v odmerku 3 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 4,6 mg/24 h.
A patient on a dose of 6 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Bolnik, ki jemlje rivastigmin peroralno v odmerku 6 mg/dan, lahko preide na zdravljenje s transdermalnimi obliži 4,6 mg/24 h.
A patient was classified as a responder if the number of letters that they could see increased, stayed the same, or fell by less than 15.
Bolnik je bil označen kot odziven, če se je število črk, ki jih je videl, povečalo, ostalo enako oziroma se zmanjšalo za manj kot 15.
A patient was classified as a ‘responder’ if the number of seizures in the second month of treatment was at least 50% lower than the number in the month before treatment was started.
Bolnik je bil razvrščen kot „odziven“, če se je število epileptičnih napadov v drugem mesecu zdravljenja z zdravilom Diacomit zmanjšalo vsaj za 50 % v primerjavi z mesecem pred uvedbo zdravila Diacomit.
A patient was classified as a ‘responder’ if they had no cancer cells in the spinal fluid after treatment and if their symptoms had not got worse after four weeks.
Bolnik je bil označen kot „odziven“, če po zdravljenju v spinalni tekočini ni imel rakavih celic in če se njihovi simptomi po štirih tednih niso poslabšali.
A patient was considered a responder in the laBCC cohort if at least one of the following criteria was met and the patient did not experience progression: (1) ≥ 30 % reduction in lesion size [sum of the longest diameter (SLD)], from baseline in target lesions by radiography; (2) ≥ 30 % reduction in SLD from baseline in externally visible dimension of target lesions; (3) Complete resolution of ulceration in all target lesions.
Za bolnika v kohorti z lokalno napredovalim bazalnoceličnim karcinomom je veljalo, da se je odzval, če je izpolnjeval vsaj eno od naslednjih meril in njegova bolezen ni napredovala: (1) ≥ 30-% zmanjšanje velikosti ciljnih lezij [seštevek najdaljših premerov (SLD – sum of the longest diameter)] od izhodišča na podlagi radiografije, (2) ≥ 30-% zmanjšanje seštevka najdaljših premerov na zunaj vidnih dimenzij ciljnih lezij od izhodišča, (3) popolna izginitev ulceracij na vseh ciljnih lezijah.
A patient was considered RBC or platelet transfusion independent during the treatment period if the subject had no RBC or platelet transfusions during any consecutive 56 days during the reporting period, respectively.
Bolnik je veljal za neodvisnega od transfuzij eritrocitov ali trombocitov med obdobjem zdravljenja, če ni imel nobene transfuzije eritrocitov oziroma trombocitov v obdobju katerih koli zaporednih 56 dni med obdobjem poročanja.
A patient was considered to have responded to treatment if their lesions reduced in area or flattened by a certain amount depending on the type of lesions.
Za bolnika se je štelo, da se je odzval na zdravljenje, če se je površina ali debelina njegovih lezij zmanjšala za določen delež, ki je odvisen od vrste lezije.
A patient who experiences dose limiting adverse reactions on either component alone may be switched to Rasilamlo containing a lower dose of that component to achieve similar blood pressure reductions.
Bolniki, pri katerih pri uporabi posameznih učinkovin zdravila pride do neželenih učinkov, zaradi katerih je treba znižati odmerek, lahko preidejo na uporabo zdravila Rasilamlo, ki vsebuje nižji odmerek te učinkovine, pri tem pa dosežejo podobno znižanje krvnega tlaka.
A patient who requires surgery while on Inflectra should be closely monitored for infections, and appropriate actions should be taken.
Bolnika, pri katerem je med zdravljenjem z zdravilom Inflectra potreben kirurški poseg, morate skrbno spremljati, da ugotovite morebitne okužbe, in uvesti ustrezne ukrepe.
A patient who requires surgery while on Remsima should be closely monitored for infections, and appropriate actions should be taken.
Bolnika, pri katerem je med zdravljenjem z zdravilom Remsima potreben kirurški poseg, morate skrbno spremljati, da ugotovite morebitne okužbe, in uvesti ustrezne ukrepe.
A patient who requires surgery while on Simponi should be closely monitored for infections, and appropriate actions should be taken.
Bolnike, ki potrebujejo kirurški poseg med zdravljenjem z zdravilom Simponi, je treba natančno spremljati, da ugotovite morebitne okužbe, in jim uvesti potrebne ukrepe.
A patient with poor metaboliser status will possess two loss-of- function alleles as defined above.
Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
A patient with such elevations of transaminases or bilirubin should stop taking naltrexone/bupropion and notify their prescribing physician.
Bolnik s tako zvišanimi vrednostmi transaminaze ali bilirubina mora prenehati jemati naltrekson/bupropion in o tem obvestiti svojega zdravnika.
A patient with type 2 diabetes previously well controlled on Efficib who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Efficib, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
A patient with type 2 diabetes previously well controlled on Janumet who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Janumet, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
A patient with type 2 diabetes previously well controlled on Ristfor who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Ristfor, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Velmetia, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio- or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Podatke posameznega bolnika so analizirali pri več kot 13.900 bolnikih z rakom (zdravljenih s kemoterapijo, radioterapijo, kemoradioterapijo ali brez zdravljenja), ki so sodelovali v 53 kontroliranih kliničnih preskušanjih z več epoetini.
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins.
Opravili so analizo podatkov na ravni bolnikov pri več kot 13.900 bolnikih z rakom (kemoterapija, radioterapija, kemoradioterapija ali brez terapije) v 53 kontroliranih kliničnih preskušanjih, ki so vključevala številne epoetine.
A patient/carer and close contacts guide
Vodnik za bolnika/negovalca in osebe, ki so v tesnem stiku z bolnikom.
a Patients were stratified by baseline HIV-1 RNA in both studies.
a Bolniki so bili v obeh študijah stratificirani po RNA ob začetku za HIV-1 RNA.
a Patients who did not complete 12 months in the study were considered to be non-responders. b Values for Disease Activity Score (DAS) are means. c Remission is defined as DAS <1.6.
a Bolniki, ki v študiji niso sodelovali 12 mesecev, so bili obravnavani kot neodzivni. b Vrednosti za oceno aktivnosti bolezni (DAS - Disease Activity Score) so povprečne vrednosti. c Remisija je definirana kot DAS < 1,6.
a Patients with at least a partial response to Humira 40 mg weekly after 12 weeks of treatment. b Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders.
a Bolniki z vsaj delnim odzivom na odmerek 40 mg Humira po 12. tednih zdravljenja. b Bolniki, ki izpolnjujejo merila, določena v protokolu za izgubo odziva ali brez izboljšanja, so bili izključeni iz študij in so še šteli pod bolnike brez odgovora (“nonresponders”).
a patients with measurable disease at baseline
a bolniki z merljivo boleznijo pred začetkom zdravljenja
A patient’s breakthrough pain was considered to have responded to treatment if there was a reduction of at least two points.
Če je prišlo pri bolniku do zmanjšanja prebijajoče bolečine za vsaj dve točki, je veljalo, da se je ta odzval na zdravljenje.
A peak Factor X level of 90% of normal is required in a 40 kg child.
Pri otroku, ki tehta 40 kg, je potrebna najvišja raven faktorja X, ki znaša 90 % običajne vrednosti.
a Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients
a Odzivi »Ped ACR« 30/50/70 so bili 48. teden značilno večji kot pri bolnikih, ki so dobivali placebo
A penile modeling procedure is performed 1 to 3 days after the second injection of each treatment cycle.
Postopek modeliranja penisa se opravi 1 do 3 dni po drugi injekciji vsakega cikla zdravljenja.
A penile modeling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle.
Postopek modeliranja penisa je bil opravljen pri bolnikih na mestu poteka študije 1 do 3 dni po drugem injiciranju v ciklu.
a Percent of patients achieving PASI75 response was calculated as center-
a Odstotek bolnikov, ki so dosegli odziv PASI 75, je bil izračunan kot delež,
A percentage of such pigs may also suffer oedema or erythema (posterior in distribution), and palpebral oedema.
Pri 1 % teh prašičev so se pojavili edemi ali rdečica (posteriorna) in palpebralni edemi.
A perfusion tubing of an inner diameter of 1 mm and a length of 150 cm must be used.
Uporabite perfuzijsko cevko notranjega premera 1 mm in dolžine 150 cm.
A peri and postnatal toxicity study performed in rabbits with thalidomide administered at doses up to 500 mg/kg/day resulted in abortions, increased stillbirths and decreased pup viability during lactation.
Perinatalna in postnatalna študija toksičnosti, izvedena pri kuncih, z odmerki talidomida do 500 mg/kg/dan je povzročila abortuse, povečano število mrtvorojenih mladičev in zmanjšano sposobnost preživetja mladičev med laktacijo.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day.
Peri- in postnatalne razvojne študije z levetiracetamom pri podganah so izvedli pri odmerkih od 70, 350 in 1800 mg/kg/dan.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day.
Peri- in postnatalno študijo razvoja so izvedli pri podganah z odmerki levetiracetama od 70, 350 in 1800 mg/kg/dan.
a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e. a thiazolidinedione) when use of a PPAR agonist is appropriate and when diet and exercise plus the PPAR agonist alone do not provide adequate glycaemic control.
z agonistom receptorja gama, aktiviranega s peroksisomskim proliferatorjem (PPAR - peroxisome proliferator-activated receptor gamma) (tj. tiazolidindionom), če je njegova uporaba primerna in če urejenost glikemije z dieto in s telesno aktivnostjo ter z zdravljenjem samo z agonistom PPAR ni zadostna.
A PET scan with florbetaben (18F) should be requested by clinicians experienced in the clinical management of neurodegenerative disorders.
PET-preiskavo s [18F]florbetabenom mora naročiti zdravnik, usposobljen za klinično obravnavo nevrodegenerativnih bolezni.
A PET scan with florbetapir (18F) should be requested by physicians skilled in the clinical management of neurodegenerative disorders.
PET-preiskavo s florbetapirjem (18F) mora naročiti zdravnik, usposobljen za klinično obravnavo nevrodegenerativnih bolezni.
A pharmacodynamic interaction
Raziskava o farmakodinamičnih
A pharmacodynamic study with exenatide demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose.
Farmakodinamične študije eksenatida so pokazale, da se pri bolnikih z diabetesom tipa 2 (n=13) popravi prva faza izločanja insulina in izboljša druga faza izločanja insulina v odzivu na bolus injekcije glukoze.
A pharmacokinetic analysis predicted a drug-related QTc interval prolongation at 80 mg of 14 msec with an upper bound of 16 msec (90% CI).
Farmakokinetična analiza je ob odmerku 80 mg predvidela z zdravilom povezano podaljšanje intervala QTc za 14 msec, z zgornjo mejo 16 msec (90 % IZ).
A pharmacokinetic analysis with TAGRISSO predicted a concentration-dependent increase in QTc interval prolongation.
Farmakokinetična analiza z zdravilom TAGRISSO je predvidela od koncentracije odvisno povečanje podaljšanja intervala QTc.
A pharmacokinetic study in paediatric patients aged 2 months to <18 years demonstrated very low plasma exposure to travoprost free acid, with concentrations ranging from below the 10 pg/mL assay limt of quantitation (BLQ) to 54.5 pg/mL.
Študija farmakokinetike pri pediatričnih bolnikih, starih od 2 mesecev do < 18 let, je pokazala zelo nizko plazemsko izpostavljenost prosti kislini travoprosta, pri čemer so se koncentracije gibale od vrednosti pod mejo merljivosti (10 pg/ml) do 54,5 pg/ml.
A pharmacokinetic study in subjects with hepatic cirrhosis (Child-Pugh grades A, B, and C) showed similar increases in exposure to brivaracetam irrespective of disease severity (50 %, 57 % and 59 %), relative to matched healthy controls. (see section 4.2)
Farmakokinetična študija pri preskušancih s cirozo jeter (stopnja Child-Pugh A, B in C) je pokazala podobna povečanja izpostavljenosti brivaracetamu ne glede na resnost bolezni (50 %, 57 % in 59 %) v primerjavi z ustreznimi zdravimi kontroliranimi preskušanci (glejte poglavje 4.2).
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat HCl revealed that 99% of the radiolabeled dose recovered in plasma was comprised of unchanged migalastat (77%) and 3 dehydrogenated O- glucuronide conjugated metabolites, M1to M3 (13%).
Farmakokinetično preskušanje s 150 mg [14C]-migalastat HCl pri zdravih moških prostovoljcih je pokazalo, da so 99 % radioaktivno označenega odmerka v plazmi predstavljali nespremenjen migalastat (77 %) in trije dehidrogenirani z O-glukuronidom konjugirani presnovki, M1 do M3 (13 %).
A pharmacokinetic trial in healthy male volunteers with 150 mg [14C]-migalastat hydrochloride revealed that approximately 77% of the radiolabeled dose was recovered in urine.
Farmakokinetično preskušanje s 150 mg [14C]-migalastat hidroklorida pri zdravih moških prostovoljcih je pokazalo, da se je približno 77 % radioaktivno označenega odmerka izločilo v urinu.